<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Luyten, G.P.M.</title>
    <link>http://repub.eur.nl/res/aut/7034/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Orbital metastases of breast cancer: Radiologic features (Article)</title>
      <link>http://repub.eur.nl/res/pub/21213/</link>
      <pubDate>2010-04-14T00:00:00Z</pubDate>
      <description>Background: We reviewed the radiologic features of 15 patients with orbital metastases originating from breast cancer. Methods: This was a retrospective consecutive case series. Fifteen consecutive patients with orbital metastases originating from breast carcinoma were identified between March 1997 and September 2008. A retrospective chart review was carried out, and the radiologic findings were reviewed. Results: The metastases were preseptal in 53%, intraconal in 60%, and both intraconal and extraconal in 33%. Lacrimal gland enlargement was noted in 33%, episcleral space involvement in 33%, bone involvement in 13%, and globe dystopia in 53%. The extraocular muscles were involved in 87%; in 60%, two or more muscles were involved. The medial and lateral rectus muscles were affected in 53% and 47%, respectively, and the inferior and superior rectus muscles in 33%. In 47% one or more radiologic features had not been noted by the radiologist, and in 20% the findings were misinterpreted as an"orbital pseudotumor."Conclusion: Orbital metastases originating from breast cancer may present heterogeneously. Orbital imaging most commonly shows unilateral and multifocal involvement of multiple extraocular muscles and intraconal and preseptal areas by an irregular lesion.</description>
    </item> <item>
      <title>Lacrimal Gland Radiosensitivity in Uveal Melanoma Patients (Article)</title>
      <link>http://repub.eur.nl/res/pub/24393/</link>
      <pubDate>2009-06-01T00:00:00Z</pubDate>
      <description>Purpose: To find a dose-volume effect for inhomogeneous irradiated lacrimal glands. Methods and Materials: Between 1999 and 2006, 72 patients (42 men and 30 women) were treated with fractionated stereotactic radiotherapy in a prospective, nonrandomized clinical trial (median follow-up, 32 months). A total dose of 50 Gy was given on 5 consecutive days. The mean of all Schirmer test results obtained ≥6 months after treatment was correlated with the radiation dose delivered to the lacrimal gland. Also, the appearance of dry eye syndrome (DES) was related to the lacrimal gland dose distribution. Results: Of the 72 patients, 17 developed a late Schirmer value &lt;10 mm; 9 patients developed DES. A statistically significant relationship was found between the received median dose in the lacrimal gland vs. reduced tear production (p = 0.000) and vs. the appearance of DES (p = 0.003), respectively. A median dose of 7 Gy/fraction to the lacrimal gland caused a 50% risk of low Schirmer results. A median dose of 10 Gy resulted in a 50% probability of DES. Conclusion: We found a clear dose-volume relationship for irradiated lacrimal glands with regard to reduced tear production and the appearance of DES. </description>
    </item> <item>
      <title>Chromosome 3 intratumor heterogeneity in uveal melanoma (Article)</title>
      <link>http://repub.eur.nl/res/pub/27237/</link>
      <pubDate>2009-02-01T00:00:00Z</pubDate>
      <description>PURPOSE. To investigate the presence of focal or diffuse heterogeneity of monosomy 3 in uveal melanoma, by using fluorescence in situ hybridization (FISH). METHODS. Direct interphase FISH in a series of 151 uveal melanomas revealed 82 tumors with loss of chromosome 3. Tumors with monosomy 3 were suspected to be heterogeneous if there were low percentages of monosomy 3, triploid clones, inconsistencies between FISH on centromere 3 and the long arm of chromosome 3, or discrepancies between fine-needle-aspiration biopsies (FNABs) and the main tumor. These tumors (n = 16), all choroidal melanomas, were selected and analyzed for intratumor heterogeneity by using FISH on paraffin-embedded tissue sections. RESULTS. Different sections of each tumor were evaluated with FISH: 6 tumors showed monosomy 3 in the same percentage throughout the tumor, and 10 showed multiple clones with different percentages of monosomy 3. However, these tumors did not show focal heterogeneity with respect to chromosome 3 status, and differences in monosomy 3 distribution between the base and apex of the tumor could not be identified. CONCLUSIONS. Although a small number of uveal melanomas show heterogeneity for chromosome 3, it does not affect survival. In the presence of triploid clones, the loss of chromosome 3 is more difficult to interpret. In general, tumor biopsies in uveal melanoma provide an accurate prediction of the patient's prognosis. Copyright </description>
    </item> <item>
      <title>Gene expression profiling in uveal melanoma: Two regions on 3p related to prognosis (Article)</title>
      <link>http://repub.eur.nl/res/pub/29410/</link>
      <pubDate>2008-10-01T00:00:00Z</pubDate>
      <description>PURPOSE. Although studies on uveal melanoma (UM) revealed prognostic significance of chromosomal aberrations, they resulted in classification errors in survival prediction. A robust prognostic classifier with strong predictive value and further insight in genes responsible for poor prognosis were obtained by performing a gene-expression profile in tumors of UM patients for which extensive clinical, histopathologic, cytogenetic, and follow-up data were available. Furthermore, the UM microarray expression data were compared with cytogenetic data. METHODS. Gene-expression profiles of 46 UMs were obtained with microchip assays. Data were analyzed with cluster-analysis and predictive analysis of microarrays (PAM) software and validated with real-time PCR. The prognostic significance of UMs with specific molecular signatures was determined. Furthermore, LAP analysis resulted in the identification of differentially expressed chromosomal regions. RESULTS. The primary UMs were classified in two distinct molecular classes with a strong prognostic value (P &lt; 0.001; hazard ratio 7.7). Classifier gene sets for microarray class and disease-free survival were validated with real-time PCR, and the predictive value of the UM class marker set was validated with gene-expression profiles of tumors provided by other institutions, showing a sensitivity of 0.93 and specificity of 1.00 for class II tumors. A locally adaptive statistical procedure identi-fied two regions on the short arm of chromosome 3 with decreased gene-expression in tumors with shorter disease-free survival. CONCLUSIONS. Microarray classification outperforms known prognostic indicators for UM, such as clinical, histopathologic, and cytogenetic parameters. In addition, the identified regions with lower expressed genes on 3p could harbor genes that are responsible for the poor prognosis of patients with UM. Copyright </description>
    </item> <item>
      <title>Expression of the SST receptor 2 in uveal melanoma is not a prognostic marker (Article)</title>
      <link>http://repub.eur.nl/res/pub/29773/</link>
      <pubDate>2008-08-07T00:00:00Z</pubDate>
      <description>Introduction: Uveal melanoma (UM) cells and neurohormone-producing cells both originate from the neural crest. Somatostatin receptors subtype 2 (SSTR2) are over-expressed in several tumors, often from neuroendocrine origin, and synthetic antagonists like octreotide and octreotate are being used as diagnostic or therapeutic agents. We investigated the SSTR2 expression in UM, and determined whether this expression was related to prognosis of the disease. Materials and methods: UM cell lines and fresh primary UM samples were tested for SSTR2 expression by autoradiography (AR) using 125I-Tyr3-octreotate. Furthermore, UM cell lines were analyzed for SSTR2 mRNA expression with quantitative real-time RT-PCR. Results: Using AR, cell-surface SSTR2 expression was demonstrated in two UM metastatic cell lines, but no expression was detected in three cell lines derived from primary UM. However, all primary and metastatic UM cell lines showed mRNA expression levels for SSTR2 using quantitative real-time RT-PCR. Only three of 14 primary UM demonstrated moderate SSTR2 expression, and this expression was not significantly associated with tumor-free survival or any tested prognostic factor. Conclusions: Based on the rare and low expression of SSTR2 found in primary UM specimens and in UM cell lines, we conclude that SSTR2 is not widely expressed in UM. Furthermore, SSTR2 expression was not associated with tumor-free survival and prognostic factors. Therefore SSTR2 is not suited as prognostic marker or therapeutic target in UM. </description>
    </item> <item>
      <title>Increased expression of p73Δex2 transcript in uveal melanoma with loss of chromosome 1p (Article)</title>
      <link>http://repub.eur.nl/res/pub/29925/</link>
      <pubDate>2008-06-01T00:00:00Z</pubDate>
      <description>The loss of chromosome 1p and chromosome 3 is associated with metastatic disease and decreased survival of uveal melanoma (UM) patients. The p53 homologues, p73 and p63, are located on chromosomes 1p and 3q, respectively. Both are able to activate p53 target genes, resulting in growth arrest, apoptosis and differentiation. N-terminally truncated isoforms of these genes may act as dominant negative inhibitors of wild-type p53 and transactivating activity. Although, p53 is frequently involved in several malignancies it does not play a major role in UM. Altered expression has been reported for both p63 and p73 in various malignancies. In this study, fluorescent in-situ hybridization was performed to identify gains or losses of p63 and p73 loci in UM. The expression of the different p63 and p73 isoforms was evaluated by reverse transcriptase PCR followed by Southern blot analysis. Furthermore, the expression pattern of the various ΔTAp73 transcripts was analysed in seven primary UMs and 11 UM-derived cell lines using isoform-specific real-time PCR. Our results indicated that the isoform p73Δex2/3 was abundantly expressed and a relative loss of the p73 locus was associated with the upregulation of p73Δex2 and TAp73 transcripts. N-terminal transactivation forms of both p73 and p63 were observed in primary and metastasis-derived cell lines, as well as in primary melanomas, but in only one of the cell lines a ΔNp63 mRNA transcript was observed. Our data suggest a potential function of p73 deletion transcripts in UM progression. </description>
    </item> <item>
      <title>Long-term Follow-up of Endothelial Cell Change after Artisan Phakic Intraocular Lens Implantation (Article)</title>
      <link>http://repub.eur.nl/res/pub/29325/</link>
      <pubDate>2008-04-01T00:00:00Z</pubDate>
      <description>Objective: To report endothelial cell densities (ECDs) and their correlation to anterior chamber depth (ACD) after implantation of the Artisan intraocular phakic lens. Design: Prospective observational case series. Participants: Three hundred eighteen eyes of 173 myopic patients treated with the Artisan iris-fixated phakic intraocular lens (IOL). Methods: Eyes with an ACD ranging between 2.89 and 4.5 mm were implanted with the Artisan phakic IOL. Endothelial cell density measurements were performed preoperatively and at each follow-up examination using a noncontact specular microscope. Main Outcome Measures: Endothelial cell density (cells per square millimeter). Results: Follow-up ranged between 1 (82 eyes) and 7 years (13 eyes) (mean, 35.3±20.7 [standard deviation] months per eye). After 3 years, there was a significant loss in ECD (P≤0.03). At 5 years, mean observed endothelial cell loss was 8.3% (5.3% corrected for a natural endothelial cell loss of 0.6% a year). Endothelial cell density loss remained progressive throughout our follow-up period. After 3 years, a significant negative correlation between ACD and endothelial cell loss was revealed (P≤0.03). Patient age, gender, refractive error, incision size, and side of the eye were not correlated to ECD loss. All corneas remained clear throughout the study. Conclusion: After 3 years, a significant ECD loss was revealed. This ECD loss was significantly negatively correlated to the ACD. We therefore suggest that eyes just meeting the minimum ECD requirement have greater ACDs to compensate for possible greater endothelial cell loss and that patients with shallow anterior chambers have higher ECDs. Artisan phakic lens implantation in young eyes narrowly meeting the minimum criteria of endothelial cell density (2000 cells/mm2) and ACD (2.6 mm) should perhaps be reevaluated, due to longer exposure to higher rates of endothelial cell loss. </description>
    </item> <item>
      <title>Regional deletion and amplification on chromosome 6 in a uveal melanoma case without abnormalities on chromosomes 1p, 3 and 8 (Article)</title>
      <link>http://repub.eur.nl/res/pub/29960/</link>
      <pubDate>2008-02-01T00:00:00Z</pubDate>
      <description>Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Loss of the long arm and gain of the short arm of chromosome 6 are frequently observed chromosomal aberrations in UM, together with loss of chromosome 1p36, loss of chromosome 3 and gain of chromosome 8. This suggests the presence of one or more oncogenes on 6p and tumor suppressor genes at 6q that are involved in UM development. Both regions, however, have not been well defined yet. Furthermore in other neoplasms gain of 6p and loss of 6q are frequently occurring events. In this case report, we describe the delineation of a partial gain on chromosome 6p and a partial deletion on 6q in a UM with the objective to pinpoint smaller candidate regions on chromosome 6 involved in UM development. Conventional cytogenetics, comparative genomic hybridization (CGH) and fluorescence in-situ hybridization (FISH) were used to delineate regions of loss and gain on chromosome 6 in this UM patient. With conventional cytogenetics a deleted region was found on chromosome 6q that was further delineated to a region ranging from 6q16.1 to 6q22 using CGH and FISH. A region of gain from 6pter to 6p21.2 was also demarcated with CGH and FISH. No other deletions or amplifications on recurrently involved chromosomes were found in this patient. This study indicates the presence of one or more tumor suppressor genes on chromosomal region 6q16.1-6q22 and the presence of one or more oncogenes on chromosomal region 6pter-6p21.2, which are likely to be important in UM and other tumors. </description>
    </item> <item>
      <title>Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma (Article)</title>
      <link>http://repub.eur.nl/res/pub/29326/</link>
      <pubDate>2008-01-01T00:00:00Z</pubDate>
      <description>PURPOSE. Mutations in the genes that control cell proliferation in cutaneous melanoma are generally uncommon in uveal melanoma. Despite the absence of known activating mutations, the RAF-MEK-ERK, or mitogen-activated protein kinase (MAPK), pathway is usually activated in uveal melanoma. An assay with increased potential to identify mutations is now available, and this study was therefore conducted to reanalyze uveal melanoma cell lines and primary tumors for this mutation. METHODS. Eleven uveal melanoma cell lines and 45 primary uveal melanomas were analyzed for mutations in exon 15 of the B-RAF gene by using pyrophosphorolysis-activated polymerization (PAP). Mutations were validated by sequencing of the PAP product. RESULTS. B-RAF mutations were detected in cell lines OCM-1 and -3 (V600E) and in six primary uveal melanomas. The V600K mutation was detected in one primary uveal melanoma, for which the V600E assay turned out to be sensitive as well. Direct sequencing of the exon 15 PCR product did not reveal the mutations found with the PAP-assay, indicating a low frequency of the mutant allele in primary samples. CONCLUSIONS. Because of the very sensitive PAP technology, B-RAF mutations were found in cell lines and primary uveal melanomas, which suggests that they may occasionally play a role in the activation of the MAPK pathway in uveal melanoma and indicates a higher prevalence of B-RAF mutations in uveal melanoma than was reported earlier. However, the relative scarcity of the B-RAF mutation excludes an elemental role for this mutation in uveal melanoma. Copyright </description>
    </item> <item>
      <title>Expression of APITD1 is not related to copy number changes of chromosomal region 1p36 or the prognosis of uveal melanoma (Article)</title>
      <link>http://repub.eur.nl/res/pub/35700/</link>
      <pubDate>2007-11-01T00:00:00Z</pubDate>
      <description>PURPOSE. Concurrent loss of chromosome arm 1p, region 36, and chromosome 3 leads to decreased disease-free survival in patients with uveal melanoma. A candidate tumor-suppressor gene APITD1 is located on the critical region on chromosome arm 1p, and it was therefore hypothesized that lower expression levels of this gene could lead to decreased survival in patients, with concurrent loss of a region on chromosome arm 1p and chromosome 3. Using neuroblastoma cells, which, like uveal melanoma, originate from neural crest cells, a former study showed that APITD1 has cell growth and/or cell death properties. In this study, APITD1 expression was analyzed to determine whether it corresponds with the DNA copy number and is related to survival in uveal melanoma. METHODS. To detect whether loss in the copy number of APITD1 results in lowered mRNA expression of the gene, FISH analysis was combined with real-time PCR. In addition, the effect of APITD1 expression on survival was studied by using Kaplan-Meier survival analysis. RESULTS. Expression of APITD1 mRNA was not related to DNA copy number (P = 0.956) or chromosome 3 status (P = 0.958). Kaplan-Meier survival analysis showed very similar survival curves for tumors with high and low APITD1 expression, with a log-rank significance value of P = 0.9682. CONCLUSIONS. These results indicate that APITD1 is not the tumor suppressor gene on 1p36 responsible for the negative prognostic effect in uveal melanoma with concurrent loss of chromosome arm 1p, region 36, and chromosome 3. Copyright </description>
    </item> <item>
      <title>Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification (Article)</title>
      <link>http://repub.eur.nl/res/pub/35302/</link>
      <pubDate>2007-08-01T00:00:00Z</pubDate>
      <description>The current clinical diagnosis of Von Hippel-Lindau (VHL) disease demands at least one specific a sporadic VHL manifestation in a patient with familial VHL disease, or, in asporadic patient, at least two or more hemangioblastomas or a single hemangioblastoma in combination with a typical visceral lesion. To evaluate this definition, we studied the frequency of germline VHL mutation in three patients groups: (i) multi-organ involvement (classic VHL), (ii) limited VHL manifestations meeting criteria (non-classic VHL) and (iii) patients with VHL-associated tumors not meeting current diagnostic VHL criteria. In addition, we validated multiplex ligation-dependent probe amplification (MLPA) as a rapid and reliable quantitative method for the identification of germline VHL deletions. The frequency of germline VHL mutations was very high in classic VHL cases with multi-organ involvement (95%), lower in non-classic cases that meet current diagnostic criteria but have limited VHL manifestations or single-organ involvement (24%) and low (3.3%), but tangible in cases not meeting current diagnostic VHL criteria. The detection of germline VHL mutations in patients or families with limited VHL manifestations, or single-organ involvement is relevant for follow-up of probands and early identification of at-risk relatives. </description>
    </item> <item>
      <title>Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13853/</link>
      <pubDate>2005-12-01T00:00:00Z</pubDate>
      <description>PURPOSE: Uveal melanoma is a highly malignant disease with a mortality rate of 50% at 10 to 15 years. Previous studies have shown that chromosomal changes are associated with decreased survival of the patient. However, in these studies the small number of tumors analyzed did not allow robust statistical analysis. In the present study, the independent numerical changes in chromosomes 1, 3, 6, and 8 on disease-free survival (DFS) was assessed in a large series of patients with uveal melanoma. METHODS: One hundred twenty tumors from patients with uveal melanoma were analyzed for numerical changes in chromosomes 1, 3, 6, and 8, with cytogenetic analysis, fluorescent in situ hybridization, and/or comparative genomic hybridization. Data were correlated with disease outcome in univariate and multivariate analyses, by Kaplan-Meier and Cox regression analyses. RESULTS: At a mean follow-up time of 45 months, 42 patients had died or had metastatic disease. In the univariate analysis, loss of chromosome 3, gain of 8q, largest tumor diameter, or the presence of epithelioid cells was associated with a decreased DFS. In the multivariate analysis, the effect of monosomy 3 on survival was largely modified by changes in 1p36. Regarding all chromosomal changes, only the concurrent loss of the short arm of chromosome 1 and all of chromosome 3 was an independent prognostic parameter for disease-free survival (P &lt; 0.001). CONCLUSIONS: In uveal melanoma, concurrent loss of the short arm of chromosome 1 and all of chromosome 3 is an independent predictor of decreased DFS.</description>
    </item> <item>
      <title>Dose fractionation effects in primary and metastatic human uveal melanoma cell lines (Article)</title>
      <link>http://repub.eur.nl/res/pub/10236/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>PURPOSE: To investigate the effects of split-dose irradiation on primary
      and metastatic uveal melanoma cell lines, with a clonogenic survival
      assay. METHODS: Appropriate cell concentrations of four primary and four
      metastatic human uveal melanoma cell lines were cultured for irradiation
      with single doses and with two equal fractions separated by 5 hours. After
      irradiation, colony formation was allowed for 7 to 21 days. Two cutaneous
      melanomas were also tested for comparison. All survival curves were
      analyzed using the linear quadratic (LQ) model. Specific parameters for
      the intrinsic radiosensitivity (alpha-component, SF2), for the capacity of
      repair of DNA damage (beta-component), as well as the alpha/beta ratio
      were calculated. RESULTS: After single-dose irradiation a wide range in
      the values of the alpha- and beta-component was obtained for both primary
      and metastatic uveal melanomas, which resulted in a wide range of
      alpha/beta ratios. In contrast, calculations based on split-dose data,
      with which the beta-component could be estimated independent of the
      alpha-component, indicated that estimates for the capacity of sublethal
      DNA damage repair was very similar in all cell lines. This indicated that
      intrinsic factors dominated the radiosensitivity of these cell lines.
      Split-dose irradiation had little influence on the intrinsic
      radiosensitivity (alpha-component), but cell survival increased for all
      cell lines. For the two cutaneous melanomas comparable split-dose results
      were obtained. CONCLUSIONS: For both primary and metastatic uveal melanoma
      cell lines, data from single and fractionated doses indicate large
      variations in radiosensitivity, which are mainly dominated by the
      intrinsic radiosensitivities. Doses of approximately 8 Gy in five
      fractions would be sufficient to eradicate 10(9) cells (approximately 1
      cm3) of the most radioresistant tumor cell lines, but this schedule is an
      overkill for the radiosensitive tumor cell lines. Based on specific
      morphologic and histologic tumor markers, more individualized dose
      fractionation schedules could improve the therapeutic ratio for uveal
      melanomas.</description>
    </item> <item>
      <title>Detection of genetic prognostic markers in uveal melanoma biopsies using fluorescence in situ hybridization (Article)</title>
      <link>http://repub.eur.nl/res/pub/9847/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>PURPOSE: In uveal melanoma, specific chromosomal abnormalities are known
      to correlate with the risk of metastases; changes in chromosomes 3 and 8q
      correlate strongly with a decreased survival of the patient, whereas
      chromosome 6 abnormalities are associated with a better prognosis.
      Usually, karyotyping and fluorescence in situ hybridization (FISH)
      analysis are used to detect these abnormalities in resected tumor tissues.
      However, the evaluation of these chromosomal changes is compromised in
      patients treated with eye-retaining treatment protocols because of the
      lack of tumor material. The purpose of this study was to validate the use
      of FISH for the analysis of genetic prognostic markers. EXPERIMENTAL
      DESIGN: We analyzed 40 uveal melanoma fine needle aspiration biopsies
      (FNABs) and the corresponding main tumor with FISH. RESULTS: All biopsies
      were found to contain tumor cells, and FISH analyses of the samples were
      successful in all cases. Statistical analysis showed very good agreement
      between the FISH results from the biopsies and those from the main tumor.
      In only 2 of 249 hybridizations did we find a small variation that could
      have led to a misclassification. CONCLUSIONS: Our results indicate that
      the application of FISH to FNABs is a reliable method for assaying genetic
      prognostic parameters such as chromosome 3 loss and/or chromosome 8q gain.
      Implementation of this method in a diagnostic setting means that we are
      able to identify patients at risk of developing metastatic disease, not
      only in enucleated patients but also in cases treated with conservative
      treatment modalities such as radiotherapy.</description>
    </item> <item>
      <title>Cellular radiosensitivity of primary and metastatic human uveal melanoma cell lines (Article)</title>
      <link>http://repub.eur.nl/res/pub/9940/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>PURPOSE: To investigate the radiosensitivity of uveal melanoma cell lines
      by a clonogenic survival assay, to improve the efficiency of the radiation
      regimen. METHODS: Four primary and four metastatic human uveal melanoma
      cell lines were cultured in the presence of conditioned medium. After
      single-dose irradiation (0-12 Gy), colonies were allowed to form for 6 to
      14 days. Two cutaneous melanomas cell lines were also tested for
      comparison. The survival curves were analyzed by the linear quadratic (LQ)
      model, and the surviving fraction at a dose of 2 Gy (SF(2)), the SF at 10
      Gy (SF(10)), the ratio of initial irreparably damaged DNA
      (alpha-coefficient) to the capacity to repair sublethally damaged DNA
      (beta-coefficient), and the plating efficiency were calculated. RESULTS:
      The melanomas displayed a wide range of initial irreparable DNA damage
      (alpha-component), as well as a capacity for repair of sublethal DNA
      damage (beta-component), which ultimately resulted in a wide range of
      alpha/beta ratios. These findings were similar in both primary and
      metastatic melanomas and were comparable with data obtained from two
      cutaneous melanomas. CONCLUSIONS: Cell lines obtained from primary and
      metastatic human uveal melanomas displayed a wide range of
      radiosensitivity, similar to that published for cutaneous melanomas.
      Translating these data to the clinical setting indicates that a
      fractionated dose of 8 to 10 Gy administered in three to four fractions,
      as currently delivered in many centers, should be sufficient to eradicate
      tumors of approximately 1 cm(3).</description>
    </item> <item>
      <title>Primary and metastatic uveal melanoma : towards a therapeutic approach (Doctoral Thesis)</title>
      <link>http://repub.eur.nl/res/pub/22515/</link>
      <pubDate>1996-06-15T00:00:00Z</pubDate>
      <description></description>
    </item>
  </channel>
</rss>